Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Liang Zeng

Showing results (591-600 of 633) with videos related to

Pageof 64
Sort By:
Journal of Clinical & Cellular Immunology|November 25, 2014
Comparative Study of Prions in Iatrogenic and Sporadic Creutzfeldt-Jakob DiseaseXiangzhu Xiao, Jue Yuan, Liuting Qing, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 20, 2013
Arabidopsis EDM2 promotes IBM1 distal polyadenylation and regulates genome DNA methylation patternsMingguang Lei, Honggui La, Kun Lu, et al.
Cancer Journal (Sudbury, Mass.)|January 23, 2026
Advanced Imaging Techniques for the Detection and Follow-up of Brain MetastasesHang Yu, Hany Soliman, Kang Liang Zeng, et al.
Journal of Neurosurgery|June 26, 2026
A novel surgical T staging system for recurrent nasopharyngeal carcinoma: advancing prognostic accuracy and clinical applicabilityHuankang Zhang, Xiaole Song, Jingyi Yang, et al.
Aging|December 14, 2016
Quiescin-sulfhydryl oxidase inhibits prion formation <i>in vitro</i>Yi-An Zhan, Romany Abskharon, Yu Li, et al.
Journal of Natural Products|March 15, 2022
Selaginellin Inhibits Melanogenesis via the MAPK Signaling PathwayYing Zhou, Hong-Liang Zeng, Xin-Yue Wen, et al.
JAMA Network Open|March 20, 2020
Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non-Small Cell Lung Cancer After Second-Line Treatment Failure: A Nonrandomized Clinical TrialXiangyu Zhang, Yi Xiong, Qing Xia, et al.
Lung Cancer (Amsterdam, Netherlands)|September 2, 2023
Dynamic cytokines signature predicts survival outcome from severe Immune-related hepatitis with PD-1/PD-L1 blockade in lung cancerLiang Zeng, Yuling Zhou, Qinqin Xu, et al.
Med (New York, N.Y.)|March 23, 2024
First-in-human phase I study of BEBT-109 in previously treated EGFR exon 20 insertion-mutated advanced non-small cell lung cancerLiang Zeng, Lianxi Song, Li Liu, et al.
Frontiers in Immunology|July 5, 2022
Vγ2 x PD-L1, a Bispecific Antibody Targeting Both the Vγ2 TCR and PD-L1, Improves the Anti-Tumor Response of Vγ2Vδ2 T CellRui Yang, Qing He, Hui Zhou, et al.
Pageof 64

Showing results (591-600 of 633) with videos related to

Sort By:
Pageof 64
Journal of Clinical & Cellular Immunology|November 25, 2014
Comparative Study of Prions in Iatrogenic and Sporadic Creutzfeldt-Jakob DiseaseXiangzhu Xiao, Jue Yuan, Liuting Qing, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 20, 2013
Arabidopsis EDM2 promotes IBM1 distal polyadenylation and regulates genome DNA methylation patternsMingguang Lei, Honggui La, Kun Lu, et al.
Cancer Journal (Sudbury, Mass.)|January 23, 2026
Advanced Imaging Techniques for the Detection and Follow-up of Brain MetastasesHang Yu, Hany Soliman, Kang Liang Zeng, et al.
Journal of Neurosurgery|June 26, 2026
A novel surgical T staging system for recurrent nasopharyngeal carcinoma: advancing prognostic accuracy and clinical applicabilityHuankang Zhang, Xiaole Song, Jingyi Yang, et al.
Aging|December 14, 2016
Quiescin-sulfhydryl oxidase inhibits prion formation <i>in vitro</i>Yi-An Zhan, Romany Abskharon, Yu Li, et al.
Journal of Natural Products|March 15, 2022
Selaginellin Inhibits Melanogenesis via the MAPK Signaling PathwayYing Zhou, Hong-Liang Zeng, Xin-Yue Wen, et al.
JAMA Network Open|March 20, 2020
Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non-Small Cell Lung Cancer After Second-Line Treatment Failure: A Nonrandomized Clinical TrialXiangyu Zhang, Yi Xiong, Qing Xia, et al.
Lung Cancer (Amsterdam, Netherlands)|September 2, 2023
Dynamic cytokines signature predicts survival outcome from severe Immune-related hepatitis with PD-1/PD-L1 blockade in lung cancerLiang Zeng, Yuling Zhou, Qinqin Xu, et al.
Med (New York, N.Y.)|March 23, 2024
First-in-human phase I study of BEBT-109 in previously treated EGFR exon 20 insertion-mutated advanced non-small cell lung cancerLiang Zeng, Lianxi Song, Li Liu, et al.
Frontiers in Immunology|July 5, 2022
Vγ2 x PD-L1, a Bispecific Antibody Targeting Both the Vγ2 TCR and PD-L1, Improves the Anti-Tumor Response of Vγ2Vδ2 T CellRui Yang, Qing He, Hui Zhou, et al.
Pageof 64